Skip to main content

WIRB to Co-present Northwest Association for Biomedical Research 2017 IRB Conference

Attendees will learn how to best manage the rapidly evolving clinical research landscape and continue to provide high quality ethical reviews

Princeton, N.J.; July 12, 2017 WIRB-Copernicus Group® (WCG™), the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced that its Western Institutional Review Board® (WIRB™) will be co-presenting the Northwest Association for Biomedical Research (NWABR) 2017 IRB Conference. This conference will be held on July 13 at the Seattle Airport Marriott, Seattle, WA. It will also be webcast live from the venue.

Acknowledging the many changes that IRBs are currently facing, this year’s NWABR conference theme is “Staying Ahead: Disruption & Ethics Review.” Attendees will discuss the best ways to prepare for adoption of the National Institutes of Health (NIH) Single IRB of Record model in January 2018 and how to continue to conduct high quality ethical reviews as the line between clinical care and research steadily blurs. They will also share best practices as the implementation of the 21st Century Cures Act and increasing adoption of mHealth technologies accelerate the pace of clinical research and increase the complexity of IRB review.

“This is an exciting and challenging time for IRBs. Advances in medical science, mhealth technologies and clinical trial designs, while good for patients, are creating a significant learning curve for IRBs who need to keep up to date with all these changes and new regulations to be able to offer the highest quality ethical reviews,” said WCG Chief Compliance Officer David Foster, JD, MA, CIP. “As a leader in the field, WCG understands this need for ongoing education and is committed to supporting valuable meetings like the NWABR IRB Conference and sharing its knowledge with colleagues in the industry.”

WCG reviews more than 3,000 new protocols per year. It has five IRBs and 11 AAHRPP-accredited panels, more than 130 experienced board members, and 50 years’ experience in protocol and study-related review.

Mr. Foster will give the conference welcoming address, together with NWABR Executive Director Ken Gordon, and Quorum CEO Cami Gearhart.

WIRB will also have experts on site to demonstrate and answer questions about its WIRB NIH Single Review Solution™ for NIH-funded multi-site research, and IRBNet, its leading compliance and research oversight solution for institutions.

Interested parties can register for the conference or the webcast at http://nwabr.events. To maximize access to this valuable meeting, WIRB is providing a 25% discount on webcast registration for participants using the code WIRBWeb25.

About WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry’s first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

About WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit wcgclinical.com or follow us on LinkedIn or X @WCGClinical.